| 2024-03-28 11:36 | CC:CZO | Ceapro Inc | 0.235 | News Release200 | Ceapro, Aeterna merger receives court approval |
| 2024-03-12 14:33 | CC:CZO | Ceapro Inc | 0.23 | News Release200 | Ceapro, Aeterna holders OK merger at March 3 meeting |
| 2024-02-26 12:40 | CC:CZO | Ceapro Inc | 0.26 | News Release200 | Aeterna, Ceapro receive proxy support for merger |
| 2024-02-23 11:36 | CC:CZO | Ceapro Inc | 0.26 | News Release200 | Ceapro talks Aeterna merger, operations update |
| 2024-02-15 18:15 | CC:CZO | Ceapro Inc | 0.18 | News Release200 | Ceapro mails information circular for March 12 meeting |
| 2023-12-14 10:31 | CC:CZO | Ceapro Inc | 0.225 | Resume Trading385 | Ceapro to resume at 8 a.m. PT |
| 2023-12-14 09:27 | CC:CZO | Ceapro Inc | 0.225 | News Release200 | Aeterna Zentaris, Ceapro sign definitive merger deal |
| 2023-12-14 07:57 | CC:CZO | Ceapro Inc | 0.225 | Halt Trading170 | Ceapro halted at the open |
| 2023-12-13 13:21 | CC:CZO | Ceapro Inc | 0.23 | News Release200 | Ceapro begins patient dosing in avenanthramides study |
| 2023-11-29 14:59 | CC:CZO | Ceapro Inc | 0.24 | News Release200 | Ceapro loses $1.04-million in Q3 2023 |
| 2023-11-29 09:03 | CC:CZO | Ceapro Inc | 0.25 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-11-29 09:03 | CC:CZO | Ceapro Inc | 0.25 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2023-11-27 11:01 | CC:CZO | Ceapro Inc | 0.25 | News Release200 | Ceapro begins study of avenanthramides for inflammation |
| 2023-11-07 11:25 | CC:CZO | Ceapro Inc | 0.305 | News Release200 | Ceapro, Natex to work on PGX tech development |
| 2023-08-29 15:27 | CC:CZO | Ceapro Inc | | News Release200 | Ceapro loses $1.15-million in Q2 |
| 2023-08-29 08:35 | CC:CZO | Ceapro Inc | 0.40 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2023-08-29 08:01 | CC:CZO | Ceapro Inc | 0.40 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-08-25 09:38 | CC:CZO | Ceapro Inc | 0.44 | News Release200 | Ceapro extends supply, distribution deal with Symrise |
| 2023-07-18 15:30 | CC:CZO | Ceapro Inc | 0.43 | News Release200 | Ceapro expands research work with Angiogenesis |
| 2023-06-07 12:56 | CC:CZO | Ceapro Inc | 0.47 | News Release200 | Ceapro shareholders approve all matters at AGSM |
| 2023-05-25 16:18 | CC:CZO | Ceapro Inc | 0.425 | News Release200 | Ceapro loses $385,000 in Q1 2023 |
| 2023-05-25 09:14 | CC:CZO | Ceapro Inc | 0.50 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-05-25 09:14 | CC:CZO | Ceapro Inc | 0.50 | SEDAR MD & A815 | SEDAR MD & A |
| 2023-05-23 11:23 | CC:CZO | Ceapro Inc | 0.50 | News Release200 | Ceapro releases positive preclinical PGX-YGB results |
| 2023-05-15 09:09 | CC:CZO | Ceapro Inc | 0.53 | SEDAR Annual Report803 | SEDAR Annual Report |
| 2023-05-03 10:37 | CC:CZO | Ceapro Inc | 0.56 | News Release200 | Ceapro releases AVE, BG research results |
| 2023-04-27 13:12 | CC:CZO | Ceapro Inc | 0.57 | News Release200 | Ceapro appoints Regnier as technical operations VP |